| 2.98 -0.17 (-5.4%) | 08-19 12:23 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.69 |
1-year : | 3.97 |
| Resists | First : | 3.15 |
Second : | 3.4 |
| Pivot price | 3.03  |
|||
| Supports | First : | 2.76 |
Second : | 2.3 |
| MAs | MA(5) : | 3.17 |
MA(20) : | 3 |
| MA(100) : | 3.61 |
MA(250) : | 4.18 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.7 |
D(3) : | 66 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 12.14 | Low : | 2.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVAX ] has closed below upper band by 48.2%. Bollinger Bands are 10.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.18 - 3.19 | 3.19 - 3.2 |
| Low: | 3.01 - 3.02 | 3.02 - 3.03 |
| Close: | 3.12 - 3.15 | 3.15 - 3.17 |
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Thu, 13 Aug 2026
Evaxion Biotech A/S (EVAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mon, 26 May 2025
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 (NASDAQ:EVAX) - Seeking Alpha
Tue, 13 May 2025
EVAX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Fri, 31 Jan 2025
Evaxion Biotech A/S Closes Public Offering Raising $10.8 Million to Advance AI-Powered Vaccine Pipeline - Quiver Quantitative
Tue, 14 Jan 2025
Evaxion Biotech - Via Ritzau
Tue, 02 Apr 2024
Earnings Call Summary | Evaxion Biotech(EVAX.US) Q4 2023 Earnings Conference - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 9.6 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.58 |
| Profit Margin | -129.7 % |
| Operating Margin | -122.1 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -83 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.9 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -3.05 |
| PEG Ratio | 0 |
| Price to Book value | 1.92 |
| Price to Sales | 3.37 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|